Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.30 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGAV | P06756 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL788096 | 0.84 | METAP2 (0.43) | METAP2METAP1ENPP1GRIN2BPTGDR2 | |
| SCHEMBL5349501 | 0.84 | METAP2 (0.43) | METAP2METAP1ENPP1GRIN2BPTGDR2 | |
| SCHEMBL788792 | 0.83 | METAP2 (0.42) | METAP2METAP1ENPP1GRIN2BPTGDR2 | |
| SCHEMBL7771672 | 0.83 | METAP2 (0.42) | METAP2METAP1ENPP1GRIN2BPTGDR2 | |
| SCHEMBL7576752 | 0.79 | METAP2 (0.42) | METAP2METAP1ENPP1NPY5R | |
| SCHEMBL19207483 | 0.79 | METAP2 (0.39) | METAP2METAP1ENPP1GRIN2BPTGDR2 | |
| SCHEMBL28203630 | 0.76 | METAP2 (0.38) | METAP2METAP1ENPP1GRIN2B | |
| SCHEMBL14125937 | 0.75 | KDM4E (0.46) | METAP2METAP1ENPP1GRIN2B | |
| SCHEMBL4521136 | 0.72 | — | — | |
| SCHEMBL9639615 | 0.72 | METAP2 (0.43) | METAP2METAP1ENPP1GRIN2BNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | DEVGEN NV (BE) | 2009-09-17 | — | — | US | disclosed |
| EP-1934181-A2 | KINASE INHIBITORS | Devgen NV (BE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042321-A2 | KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | ROCK1, MAP3K1, MAP3K11 | METAP2 3709/4885METAP1 2493/4885ENPP1 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.